Merck’s Japan unit files for approval of oral coronavirus treatment
December 3, 2021
MSD K.K., a subsidiary of U.S. pharmaceutical company Merck & Co., filed an application for approval of the oral coronavirus treatment molnupiravir to the Health, Labor and Welfare Ministry on Friday.
If approved, it will be the first drug to be used in Japan for the treatment of the novel coronavirus.
The government wants the drug to be available for practical use by the end of this year.
It is said that the risk of serious illness is reduced if people with mild symptoms take the antiviral drug early in the course of the disease. In clinical trials, the drug was found to be effective in reducing the risk of serious illness by 30%, according to Merck.
The treatment has already been approved in Britain.
Japan has agreed to receive a supply of 1.6 million doses, on the assumption that the regulatory authority will swiftly approve the drug.
"Society" POPULAR ARTICLE
-
M6.0 Earthquake Hits Japan’s Tohoku Region; Fukushima, Iwate, Miyagi Prefectures Observe 4 on Japanese Scale With No Risk of Tsunami
-
Shinkansen Services Suspended After Man ‘Searches for Phone’ on Tracks; Disruption Affects About 14,000 Passengers
-
Whaling Mother Ship Built in Japan for 1st Time in 73 Years
-
U.S. 7th Fleet officer Arrested on Suspicion of Stealing Sushi, Sashimi, Chicken at Kanagawa Shopping Mall; Suspect Caught Mid-Meal
-
Tsunami Advisory for Okinawa Lifted at Noon (UPDATE 2)
JN ACCESS RANKING
- M6.0 Earthquake Hits Japan’s Tohoku Region; Fukushima, Iwate, Miyagi Prefectures Observe 4 on Japanese Scale With No Risk of Tsunami
- Cherry Blossoms Draw Crowd to Tokyo’s Ueno Park; Viewing Season Kicks Off to Slow Start
- China Mutes Memorialization of Reformer Hu Yaobang; Memories Could Spark Critique of Xi Administration
- Shinkansen Services Suspended After Man ‘Searches for Phone’ on Tracks; Disruption Affects About 14,000 Passengers
- Whaling Mother Ship Built in Japan for 1st Time in 73 Years